The best peptides for bone health are not supplements but two prescription drugs: teriparatide and abaloparatide. Both are FDA-approved for osteoporosis at high fracture risk, and in large trials they cut new spine fractures by roughly two-thirds or more versus placebo (5% vs 14% for teriparatide; 0.6% vs 4.2% for abaloparatide).[2][7] Calcitonin is an older peptide with weaker evidence and a cancer warning, and collagen peptides have one modest bone-density trial.[9][10]
Bone is the clearest example on this site of the gap between approved peptide drugs and unproven “healing” peptides. This guide is part of our healing peptides hub.
Evidence-graded table
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Bisphosphonates, denosumab (not peptides) | FDA-approved for this use | Reduce fractures; usual first-line options[1] | Approved | Not applicable |
| Teriparatide (Forteo and generics) | FDA-approved for this use | Spine fractures 5% vs 14% on placebo; beat risedronate in severe osteoporosis[2][3] | Approved: women and men at high fracture risk, steroid-induced osteoporosis[4] | Teriparatide |
| Abaloparatide (Tymlos) | FDA-approved for this use | Spine fractures 0.6% vs 4.2% on placebo at 18 months[7] | Approved: postmenopausal women and men at high risk[7] | Abaloparatide |
| Calcitonin-salmon (nasal spray, injection) | FDA-approved (limited use) | 200 IU spray cut spine fractures 33% in PROOF; label says fracture benefit not demonstrated for the spray product[8][9] | Approved with restrictions; malignancy warning | Not applicable |
| Collagen peptides | Human RCTs (one trial) | Small gains in spine and hip density over 12 months[10] | Dietary supplement; not approved to treat anything | Not applicable |
| BPC-157, TB-500 | No evidence for bone in humans | Not tested for osteoporosis in people | Not approved | BPC-157 |
Start with the basics and first-line drugs
The Endocrine Society’s osteoporosis guideline sets four principles: estimate each woman’s fracture risk with a validated tool, include her preferences, pair every drug with nutrition, exercise and fall prevention, and recognize that several medicines reduce fractures with acceptable safety.[1] For most people, the first drugs are bisphosphonates (such as alendronate) or denosumab.
Calcium and vitamin D, weight-bearing and balance exercise, stopping smoking and limiting alcohol support all of these treatments.
Teriparatide: the original bone-building peptide
Teriparatide is the first 34 amino acids of human parathyroid hormone. Given as a small daily injection, it stimulates bone-forming cells rather than slowing bone breakdown.
- Pivotal trial (2001): in postmenopausal women with osteoporosis, new spine fractures occurred in 14% on placebo versus 5% on 20 mcg daily. Non-spine fragility fractures fell from 6% to 3%, and spine density rose 9% more than placebo.[2]
- VERO (2018): in 1,360 women with severe osteoporosis, new spine fractures over 24 months were 5.4% on teriparatide versus 12.0% on risedronate, a widely used bisphosphonate.[3]
The label covers postmenopausal women and men at high fracture risk, plus steroid-induced osteoporosis.[4] Its original boxed warning about bone cancer (osteosarcoma), based on high-dose rat studies, was removed in 2020 after large real-world studies found no increase in people, and the strict 2-year lifetime limit was relaxed.[5] The label still advises avoiding it in people at higher osteosarcoma risk, such as those with Paget’s disease or prior skeletal radiation.[4]
Access and cost
Teriparatide is no longer brand-only. Several versions are on the market, and in December 2025 FDA approved a generic teriparatide injection under an abbreviated application (ANDA 213641).[13] Because these are prescription drugs, insurance plans usually require proof of high fracture risk, such as a prior fragility fracture or a very low bone density score, and often prior authorization. Ask your clinician’s office to check which version your plan prefers before you start, since daily injections for up to two years add up.
Abaloparatide: a newer PTHrP analog
Abaloparatide mimics parathyroid hormone-related protein. In the ACTIVE trial of 2,463 postmenopausal women, it reduced new spine and non-spine fractures over 18 months versus placebo, and caused less high blood calcium than teriparatide (3.4% vs 6.4%).[6] Its label reports new spine fractures in 0.6% versus 4.2% on placebo, and it was later approved for men with osteoporosis at high fracture risk.[7] Use beyond 2 years in a lifetime is not recommended, and dizziness or fast heartbeat after the first doses is common, so the first injection is given sitting or lying down.[7]
Researchers are also testing these drugs around orthopedic surgery, for example abaloparatide before knee replacement.[12]
Calcitonin: an older peptide with caveats
Calcitonin-salmon is a 32-amino-acid hormone. In the five-year PROOF trial, 200 IU of nasal spray daily reduced new spine fractures by 33% versus placebo, though the 100 IU and 400 IU doses did not show a significant effect.[8]
Today’s nasal spray label is restrictive. It limits use to women more than 5 years past menopause when alternatives are not suitable, states that fracture reduction has not been demonstrated, and warns that a meta-analysis of 21 trials suggested more cancers in calcitonin-treated patients.[9] It is now rarely a first choice for osteoporosis.
Collagen peptides: a modest supplement signal
In a randomized trial of 131 postmenopausal women with low bone density, 5 g of specific collagen peptides daily for 12 months modestly increased spine and hip density scores compared with placebo, and shifted bone markers toward formation.[10] A follow-up of 31 women without a control group reported continued gains.[11] No trial has shown fewer fractures, and the research came from a group working with a collagen research institute. Treat collagen as a protein source, not an osteoporosis drug.
Why “healing peptides” don’t belong in this list
BPC-157, TB-500 and similar compounds are often marketed for “bone and joint repair.” None has a human osteoporosis or fracture-healing trial. Our BPC-157 clinical trials guide lists every human report, and our FDA-approved peptides list shows where teriparatide and abaloparatide sit among approved drugs.
Questions for your clinician
- What is my 10-year fracture risk, and do I need medication?
- Am I a candidate for a bone-building drug first, or a bisphosphonate?
- What should follow teriparatide or abaloparatide when the course ends?
- Do I need calcium, vitamin D or a protein supplement?
For more on bone after menopause, see peptides for menopause, and for joint pain, our guide to the best peptides for joint health.
